Darapladib and atherosclerotic plaque: Should lipoprotein-associated phospholipase A2 be a therapeutic target?

Current Atherosclerosis Reports

Volumn 11, Issue 5, 2009, Pages 334-337

  McCullough, Peter A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; DARAPLADIB; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG BIOAVAILABILITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; HISTIOCYTE; HUMAN; MACROPHAGE; MAST CELL; NONHUMAN; REVIEW; T LYMPHOCYTE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ATHEROSCLEROSIS; BENZALDEHYDES; HUMANS; OXIMES; TREATMENT OUTCOME;

EID: 68449083214     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0050-6     Document Type: Review

References (16)

1. Lavi S, McConnell JP, Rihal CS, et al.: Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: Association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007, 29:115:2715-2721.
2. Kolodgie FD, Burke AP, Skorija KS, et al.: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2523-2529.
3. The Lp-PLA2 Studies Collaboration, Ballantyne C, Cushman M, et al.: Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007, 14:3-11.
4. Stafforini DM, Tjoelker LW, McCormick SP, et al.: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 1999, 274:7018-7024.
5. Persson M, Hedblad B, Nelson JJ, et al.: Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007, 27:1411-1416.
6. Oei HH, van der Meer IM, Hofman A, et al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation 2005, 111:570-575.
7. Wilensky RL, Shi Y, Mohler ER 3rd, et al.: Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008, 14:1059-1066.
8. Mohler ER 3rd, Ballantyne CM, Davidson MH, et al.: The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008, 51:1632-1641.
9. Serruys PW, García-García HM, Buszman P, et al.: Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118:1172-1182.
10. McCullough PA, Lepor NE: Lipids, biomarkers, and noninvasive imaging of atherosclerotic disease activity in clinical trials. Rev Cardiovasc Med 2008, 9:142-149.
11. Daniels LB, Laughlin GA, Sarno MJ, et al.: Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: The Rancho Bernardo Study. J Am Coll Cardiol 2008, 51:913-919.
12. Robins SJ, Collins D, Nelson JJ, et al.: Cardiovascular events with increased lipoprotein-associated phospholipase A2 and low high-density lipoprotein-cholesterol. The Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2008, 28:1172-1178.
13. Nambi V: The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 2005, 7:127-131.
14. Aquilante CL, Kosmiski LA, Knutsen SD, et al.: Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism 2008, 57:494-501.
15. Miller WM, Nori Janosz KE, Yanez J, et al.: Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. Expert Rev Cardiovasc Ther 2005, 3:743-759.
16. Prospective Studies Collaboration, Lewington S, Whitlock G, et al.: Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.